MEDP Insider Notice: 38,013 Shares via UBS on NASDAQ Aug 27, 2025

Rhea-AI Filing Summary

Form 144/A from Medpace Holdings, Inc. (MEDP) reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025 with an aggregate market value of $18,056,175.00. The shares were acquired on 02/15/2022 by option exercise from the issuer and paid for in cash on 03/01/2022. The filing lists 28,741,609 shares outstanding for the class. The notice also discloses a recent sale by August J Troendle of 48,487 shares on 07/28/2025 for gross proceeds of $21,900,851.00. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing exercised options and planned market sale; amounts are disclosed precisely.

The filing documents a proposed sale of 38,013 shares via a broker with full acquisition details: acquisition by option exercise on 02/15/2022 and cash payment on 03/01/2022. It also discloses a contemporaneous sale by August J Troendle of 48,487 shares on 07/28/2025. For investors, this is a standard Rule 144/A compliance disclosure and provides transparency on insider liquidity events rather than operational updates.

Compliance/Risk Analyst

TL;DR: The filing appears procedurally complete and includes required attestations and broker details.

The notice includes broker name and address, share counts, market values, acquisition method, payment details, and recent selling history, satisfying typical Rule 144/A disclosure requirements. The signer affirms no undisclosed material adverse information. There are no indications of missing procedural elements within the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	38013	18056175.00	28741609	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2022	Option Exercise	Issuer			38013	03/01/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
August J Troendle 5375 Medpace Way Cincinnati OH 45227	Common	07/28/2025	48487	21900851.00

144/A: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the MEDP Form 144/A propose to sell?

The filing proposes to sell 38,013 common shares of Medpace Holdings, Inc.

When is the proposed sale scheduled and on which exchange will it occur?

The proposed sale is scheduled for 08/27/2025 and the securities are to be sold on NASDAQ through UBS Financial Services.

How and when were the shares being sold acquired?

The shares were acquired on 02/15/2022 by option exercise from the issuer and paid for in cash on 03/01/2022.

What recent insider sale is disclosed in the filing?

The filing shows August J Troendle sold 48,487 common shares on 07/28/2025 for gross proceeds of $21,900,851.00.

What does the filer represent about material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.